ATOSSA THERAPEUTICS, INC. 8-K

What Happened

• On April 13, 2026, Atossa Therapeutics, Inc. entered into a Settlement Agreement with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc.; the Company announced the agreement on April 16, 2026.
• The settlement is intended to resolve patent disputes and pending PTAB (Patent Trial and Appeal Board) proceedings related to Endoxifen-related intellectual property, including challenges Intas brought against two Atossa patents.

Key Details

• Parties: Atossa Therapeutics, Intas Pharmaceuticals Ltd., and Jina Pharmaceuticals, Inc.
• Date of Settlement Agreement: April 13, 2026; announcement filed on Form 8-K on April 16, 2026.
• Affected patents: Atossa’s two issued U.S. patents titled “Methods for Making and Using Endoxifen” (U.S. Pat. Nos. 11,261,151 and 12,071,391) — expected to remain issued and enforceable if PTAB proceedings are terminated as anticipated.
• Agreement terms: the parties agreed to seek termination of the identified PTAB proceedings; if any proceeding is not fully terminated, the parties agreed not to continue participating or appealing (subject to the Settlement Agreement). The agreement also includes mutual covenants not to challenge certain specified Endoxifen-related patents and preserves Atossa’s ability to develop and commercialize Z‑endoxifen base in its core areas (oncology, endocrine dysfunction disorders, and muscular dystrophy-related diseases).

Why It Matters

• For investors, the settlement reduces legal uncertainty around Atossa’s Endoxifen patent portfolio and supports the company’s plans to continue clinical development and commercialization of Z‑endoxifen base in its focused therapeutic areas.
• If the PTAB proceedings are terminated as expected, Atossa’s two challenged patents are likely to remain enforceable against third parties, which could help protect market exclusivity for relevant uses and formulations.
• The filing also notes that the outcomes are subject to PTAB action and other risks; the Company included standard forward‑looking statement disclaimers and identified related risks in its SEC filings.